Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2].
説明 | Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2]. |
In vitro | Brolucizumab, at a concentration of 2683 nM, inhibits VEGF-A112-induced phosphorylation of VEGFR1 in U87MG human glioblastoma cells and phosphorylation of VEGFR2 in ZHE-483-2 GMEC [1]. |
In vivo | Brolucizumab, administered intraperitoneally (15 mg/kg; i.p. 5 days per week for either 21 or 41 days), has been shown to slow the growth of mSLK-KSHV xenograft tumors [2]. Similarly, dosages ranging from 5-50 mg/kg given intraperitoneally once or twice daily for 28 days can delay tumor growth in the U87MG glioblastoma model [1]. Additionally, when administered intravenously (10 mg/kg; i.v.) to mice, brolucizumab exhibits a rapid elimination half-life of 5.4-7.8 minutes and a slow elimination half-life of 1.4-1.9 hours [2]. |
別名 | DLX1008, ESBA 1008, RTH258 |
分子量 | N/A |
CAS No. | 1531589-13-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Brolucizumab 1531589-13-5 Angiogenesis Tyrosine Kinase/Adaptors VEGFR DLX1008 ESBA 1008 RTH258 Inhibitor inhibitor inhibit